

Appendix 5

FORMS RELATING TO LISTING

FORM F

The Growth Enterprise Market (GEM)

Company Information Sheet

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this information sheet, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this information sheet.

Company name : **Changchun Da Xing Pharmaceutical Company Limited**

Stock code (ordinary shares) : **8067**

This information sheet contains certain particulars concerning the above company (the "Company") which is listed on the Growth Enterprise Market ("GEM") of The Stock Exchange of Hong Kong Limited (the "Exchange"). These particulars are provided for the purpose of giving information to the public with regard to the Company in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the "GEM Listing Rules"). They will be displayed at the GEM website on the Internet. This information sheet does not purport to be a complete summary of information relevant to the Company and/or its securities.

The information in this sheet was updated as of 26th June, 2002

A. General

Place of incorporation : the People's Republic of China

Date of initial listing on GEM : 28th July, 2002

Name of Sponsors : CSC Asia Limited and

Names of directors : **Executive Directors**
Mr. Feng Zhen Wen
Mr. Lu De Yi
Ms. Li Xiu Jie
Mr. Yu Cheng Kun
Mr. Guo Bin

Independent non-executive Directors
Mr. Yang Shi Jie
Mr. Sun Xiao Bo

Name of substantial shareholder (as such term is defined in rule 1.01 of the GEM Listing Rules) and its interests in the share capital and other securities of the Company	:	Changchun Kuancheng Pharmaceutical Factory, which is interested in 172,000,000 Domestic Shares, representing approximately 30.66% of the share capital of the Company
Name(s) of company(ies) listed on GEM or the Main Board of the Stock Exchange within the same group as the Company	:	N/A
Financial year end date	:	31 st December
Registered address	:	22 Kaixuan Road Kuancheng District Changchun Jilin Province the People's Republic of China
Head office and principal place of business	:	23 rd Floor Shum Tower 268 Des Voeux Road Central Hong Kong
Web-site address	:	N/A
Share registrar	:	Hong Kong Registrars Limited Shops 1712-1716, 17 th Floor Hopewell Centre 183 Queen's Road East Wan Chai Hong Kong
Auditors	:	Horwath Hong Kong CPA Limited <i>Certified Public Accountants</i> 2001 Central Plaza 18 Harbour Road Wanchai Hong Kong

B. Business activities

The Company is principally engaged in the manufacture and sale of Chinese medicines and Western medicines in the PRC under the Company's brand name Chunyan (春燕). It is also engaged in the research and development of Chinese medicines, Western medicines and biochemical medicines.

C. Ordinary shares

Number of ordinary shares in issue	:	400,000,000 Domestic Shares in issue 161,000,000 H Shares issued pursuant to the Placing
------------------------------------	---	---

Par value of ordinary shares in issue : RMB0.10

Board lot size (in number of shares) : 5,000

Name of other stock exchange(s) on which Ordinary shares are also listed : N/A

D. Warrants

Nil.

E. Other securities

Details of any other securities in issue.

(i.e. other than the ordinary shares of described in C above and warrants described in D above but including options granted to executives and/or employees).

N/A

Responsibility statement

The directors of the Company (the “Directors”) as at the date hereof hereby collectively and individually accept full responsibility for the accuracy of the information contained in this information sheet (“the Information”) and confirm, having made all reasonable inquiries, that to the best of their knowledge and belief the Information is accurate and complete in all material respects and not misleading and that there are no other matters the omission of which would make any Information inaccurate or misleading.

The Directors also collectively and individually accept full responsibility for submitting a revised information sheet, as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.

The Directors acknowledge that the Exchange has no responsibility whatsoever with regard to the Information and undertake to indemnify the Exchange against all liability incurred and all losses suffered by the Exchange in connection with or relating to the Information.

Signed:

Feng Zhen Wen
Director

Feng Zhen Wen
Director
(As attorney for Lu De Yi)

Li Xiu Jie
Director

Feng Zhen Wen
Director
(As attorney for Yu Cheng Kun)

Guo Bin
Director

Feng Zhen Wen
Director
(As attorney for Yang Shi Jie)

Feng Zhen Wen
Director
(As attorney for Sun Xiao Bo)